Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines

BACKGROUND: Osimertinib is a third-generation EGFR-TKI with a high selective potency against T790M-mutant NSCLC patients. Considering that osimertinib can lead to enhanced HER-2 expression on cell surface and HER-2 overexpression is a mechanism of resistance to osimertinib, this study was addressed...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Exp Clin Cancer Res
Main Authors: La Monica, Silvia, Cretella, Daniele, Bonelli, Mara, Fumarola, Claudia, Cavazzoni, Andrea, Digiacomo, Graziana, Flammini, Lisa, Barocelli, Elisabetta, Minari, Roberta, Naldi, Nadia, Petronini, Pier Giorgio, Tiseo, Marcello, Alfieri, Roberta
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2017
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5716361/
https://ncbi.nlm.nih.gov/pubmed/29202823
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-017-0653-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados